This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsEnphys Acquisition（NFSC.F）株式概要Enphys Acquisition Corp.は重要な事業を行っていない。 詳細NFSC.F ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績2/6財務の健全性1/6配当金0/6報酬当社が推定した公正価値より92.9%で取引されている リスク分析マイナスの株主資本 収益が 100 万ドル未満 ( $0 )株式の流動性は非常に低い 多額の負債を抱えている すべてのリスクチェックを見るNFSC.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$11.16該当なし内在価値ディスカウントEst. Revenue$PastFuture-42m15m2016201920222025202620282031Revenue US$1.0Earnings US$0AdvancedSet Fair ValueView all narrativesEnphys Acquisition Corp. 競合他社Forest Road Acquisition IISymbol: NYSE:FRXBMarket cap: US$137.9mBattery Future AcquisitionSymbol: OTCPK:BFAC.FMarket cap: US$126.8mZalatoris II AcquisitionSymbol: OTCPK:ZLSS.FMarket cap: US$125.6mJuniper IISymbol: NYSE:JUNMarket cap: US$129.7m価格と性能株価の高値、安値、推移の概要Enphys Acquisition過去の株価現在の株価US$11.1652週高値US$11.1752週安値US$10.59ベータ-0.0131ヶ月の変化-0.089%3ヶ月変化0.90%1年変化4.69%3年間の変化15.53%5年間の変化n/aIPOからの変化n/a最新ニュースお知らせ • Dec 31Enphys Acquisition Corp. Units, Each Consisting of One Class A Ordinary Share and One-Half of One Redeemable Warrant Deleted from OTC EquityEnphys Acquisition Corp. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant has been deleted from OTC Equity effective December 30, 2024, due to Unit Separation.お知らせ • Nov 15Enphys Acquisition Corp. Files Form 15Enphys Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one Class A ordinary share, and one-half of one redeemable warrant; Class A ordinary shares included as part of the Units, par value $0.0001 per share and Redeemable warrants included as part of the Units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.お知らせ • Oct 17The Staff of NYSE Regulation Files Form 25 with the SEC to Remove Enphys Acquisition's Class A Ordinary Shares, Units from Listing and Registration on the New York Stock ExchangeAs previously reported by Enphys Acquisition Corp. (the ‘Company’), on July 24, 2024, the staff of NYSE Regulation (the ‘Staff’), on behalf of the New York Stock Exchange (‘NYSE’), commenced proceedings to delist the Company’s Class A ordinary shares, par value $0.0001 per share (‘Class A Ordinary Shares’), units, each consisting of one Class A Ordinary Share and one-half of one redeemable warrant (the ‘Units’), with each warrant exercisable for one share of Class A Ordinary Share of the Company (the ‘Warrants’), and Warrants from the NYSE pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. Trading in the Class A Ordinary Shares, Units, and Warrants on the NYSE was suspended after the market closed on July 24, 2024. Effective as of and since July 25, 2024, the Class A Ordinary Shares, Units, and Warrants have been quoted and traded on the OTC Pink Marketplace under the ticker symbols ‘NFSCF,’ ‘NFSUF,’ and ‘NFSWF,’ respectively. The Company timely exercised its right to a review of the Staff’s determination by a committee (the ‘Committee’) of the Board of Directors of the NYSE. On October 10, 2024, the Company withdrew its request for review by the Committee. On October 10, 2024, the Staff filed a Form 25 with the Securities and Exchange Commission (the ‘SEC’) to remove the Company’s Class A Ordinary Shares, Units, and Warrants from listing and registration on the NYSE. The delisting will be effective 10 days following the date of filing of the Form 25. The Company’s Class A Ordinary Shares, Units, and Warrants will continue to trade on the OTC Pink Marketplace following the delisting.お知らせ • Aug 14Enphys Acquisition Corp. announced delayed 10-Q filingOn 08/13/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 26NYSE to Commence Delisting Proceedings Against Enphys AcquisitionThe New York Stock Exchange LLC announced that the staff of NYSE Regulation has determined to commence proceedings to delist Class A ordinary shares, par value 0.0001 per share; Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant and Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary shares at an exercise price of 11.50 of Enphys Acquisition Corp. (the “Company”) from the NYSE. Trading in the Company’s Securities will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s Securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s Securities upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.お知らせ • May 17Enphys Acquisition Corp. announced delayed 10-Q filingOn 05/15/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Dec 31Enphys Acquisition Corp. Units, Each Consisting of One Class A Ordinary Share and One-Half of One Redeemable Warrant Deleted from OTC EquityEnphys Acquisition Corp. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant has been deleted from OTC Equity effective December 30, 2024, due to Unit Separation.お知らせ • Nov 15Enphys Acquisition Corp. Files Form 15Enphys Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one Class A ordinary share, and one-half of one redeemable warrant; Class A ordinary shares included as part of the Units, par value $0.0001 per share and Redeemable warrants included as part of the Units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.お知らせ • Oct 17The Staff of NYSE Regulation Files Form 25 with the SEC to Remove Enphys Acquisition's Class A Ordinary Shares, Units from Listing and Registration on the New York Stock ExchangeAs previously reported by Enphys Acquisition Corp. (the ‘Company’), on July 24, 2024, the staff of NYSE Regulation (the ‘Staff’), on behalf of the New York Stock Exchange (‘NYSE’), commenced proceedings to delist the Company’s Class A ordinary shares, par value $0.0001 per share (‘Class A Ordinary Shares’), units, each consisting of one Class A Ordinary Share and one-half of one redeemable warrant (the ‘Units’), with each warrant exercisable for one share of Class A Ordinary Share of the Company (the ‘Warrants’), and Warrants from the NYSE pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. Trading in the Class A Ordinary Shares, Units, and Warrants on the NYSE was suspended after the market closed on July 24, 2024. Effective as of and since July 25, 2024, the Class A Ordinary Shares, Units, and Warrants have been quoted and traded on the OTC Pink Marketplace under the ticker symbols ‘NFSCF,’ ‘NFSUF,’ and ‘NFSWF,’ respectively. The Company timely exercised its right to a review of the Staff’s determination by a committee (the ‘Committee’) of the Board of Directors of the NYSE. On October 10, 2024, the Company withdrew its request for review by the Committee. On October 10, 2024, the Staff filed a Form 25 with the Securities and Exchange Commission (the ‘SEC’) to remove the Company’s Class A Ordinary Shares, Units, and Warrants from listing and registration on the NYSE. The delisting will be effective 10 days following the date of filing of the Form 25. The Company’s Class A Ordinary Shares, Units, and Warrants will continue to trade on the OTC Pink Marketplace following the delisting.お知らせ • Aug 14Enphys Acquisition Corp. announced delayed 10-Q filingOn 08/13/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 26NYSE to Commence Delisting Proceedings Against Enphys AcquisitionThe New York Stock Exchange LLC announced that the staff of NYSE Regulation has determined to commence proceedings to delist Class A ordinary shares, par value 0.0001 per share; Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant and Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary shares at an exercise price of 11.50 of Enphys Acquisition Corp. (the “Company”) from the NYSE. Trading in the Company’s Securities will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s Securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s Securities upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.お知らせ • May 17Enphys Acquisition Corp. announced delayed 10-Q filingOn 05/15/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Enphys Acquisition Corp. announced delayed annual 10-K filingOn 04/01/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Feb 15High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. CEO & Director Jorge De Cajal is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Nov 17Enphys Acquisition Corp. announced delayed 10-Q filingOn 11/15/2023, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 31Enphys Acquisition Corp. announced that it has received $0.3 million in fundingEnphys Acquisition Corp. announced a private placement of non-convertible promissory note to Enphys Acquisition Sponsor LLC in the principal amount of $300,000 on October 30, 2023. The issuance of the Promissory Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended. Under the terms of the promissory note, the company may request from time to time prior to the maturity date, up to $300,000 in drawdowns on the principal. Each drawdown request must state the amount to be drawn down, and must not be an amount less than $10,000 unless agreed upon by the company and the payee. Payee shall fund each drawdown request no later than (3) business days after receipt of a drawdown request; provided, however, that the maximum amount of drawdowns outstanding under the promissory note at any time may not exceed $300,000. No fees, payments or other amounts shall be due to the payee in connection with, or as a result of, any drawdown request by the company.お知らせ • Oct 11Enphys Acquisition Corp. announced that it expects to receive $0.4 million in fundingEnphys Acquisition Corp. announced a private placement of non-convertible promissory note to Enphys Acquisition Sponsor LLC in the principal amount of $400,000 on October 10, 2023. Payee or one or more of its affiliates or designees will deposit into the company’s trust account established in connection with its initial public offering an amount equal to the lesser of $0.025 per Class A ordinary share of the company multiplied by the number of Class A ordinary shares of the Company then outstanding and $100,000, for each calendar month until the earlier of the company’s completion of a business combination and February 8, 2024. No interest shall be payable on this note.お知らせ • May 16Enphys Acquisition Corp. announced delayed 10-Q filingOn 05/15/2023, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 16Enphys Acquisition Corp. announced delayed 10-Q filingOn 11/15/2022, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Enphys Acquisition Corp. announced delayed 10-Q filingOn 05/16/2022, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 23Enphys Acquisition Announces Receipt of Notice of Late Filing from New York Stock ExchangeOn April 18, 2022, Enphys Acquisition Corp. ("the Company") received a notice from the New York Stock Exchange ("the NYSE") indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed CompanyManual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2021 ("the Form 10-K") with the Securities and Exchange Commission ("the SEC"). The NYSE informed the Company that, under NYSE rules, the Company will have six months from April 18, 2022 to file the Form 10-K with the SEC. The Company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-K. If the Company fails to file the Form 10-K before the NYSE's compliance deadline, the NYSE may grant, at its sole discretion, an extension of up to six additional months for the Company to regain compliance, depending on the specific circumstances. The notice from the NYSE also notes that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant. Reference is made to the Notification of Late Filing on Form 12b-25 filed by the Company with the Commission on April 1, 2022 (the Form 12b-25") reporting that it required additional time to complete the Form 10-K. Although the Company has dedicated significant resources to the completion of finalizing its audited consolidated financial statements and related disclosures for inclusion in the Form 10-K, the Company is unable to file the Form 10-K prior to April 15, 2022, the extension period provided by the Form 12b-25. Additional time is needed by the Company to complete its review of the financial statements included in the Form 10-K in order to ensure a complete, accurate Annual Report. The delay is due primarily to additional information needed in relation to the Company's financial statements to complete the audit. The Company is working diligently to ensure accurate disclosures are made in the Form 10-K and expects to file the Form 10-K on or about April 27, 2022, or soon thereafter.お知らせ • Apr 03Enphys Acquisition Corp. announced delayed annual 10-K filingOn 04/01/2022, Enphys Acquisition Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.株主還元NFSC.FUS Capital MarketsUS 市場7D0%-0.02%1.0%1Y4.7%10.3%28.7%株主還元を見る業界別リターン: NFSC.F過去 1 年間で10.3 % の収益を上げたUS Capital Markets業界を下回りました。リターン対市場: NFSC.Fは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is NFSC.F's price volatile compared to industry and market?NFSC.F volatilityNFSC.F Average Weekly Movementn/aCapital Markets Industry Average Movement3.6%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: NFSC.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のNFSC.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2021n/aJorge De Cajalenphyspac.comEnphys Acquisition Corp.は、重要な事業を行っていない。1つまたは複数の事業との合併、株式交換、資産買収、株式購入、組織再編、または同様の企業結合を行うことに重点を置いている。再生可能エネルギーを中心としたエネルギー転換と持続可能性をテーマとする。同社は2021年に設立され、ニューヨーク州ニューヨークを拠点としている。もっと見るEnphys Acquisition Corp. 基礎のまとめEnphys Acquisition の収益と売上を時価総額と比較するとどうか。NFSC.F 基礎統計学時価総額US$135.64m収益（TTM）US$7.53m売上高(TTM)n/a18.0xPER（株価収益率0.0xP/SレシオNFSC.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NFSC.F 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用-US$7.53m収益US$7.53m直近の収益報告Jun 30, 2024次回決算日該当なし一株当たり利益（EPS）0.62グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-8.6%NFSC.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/12/31 11:50終値2024/12/17 00:00収益2024/06/30年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Enphys Acquisition Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Dec 31Enphys Acquisition Corp. Units, Each Consisting of One Class A Ordinary Share and One-Half of One Redeemable Warrant Deleted from OTC EquityEnphys Acquisition Corp. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant has been deleted from OTC Equity effective December 30, 2024, due to Unit Separation.
お知らせ • Nov 15Enphys Acquisition Corp. Files Form 15Enphys Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one Class A ordinary share, and one-half of one redeemable warrant; Class A ordinary shares included as part of the Units, par value $0.0001 per share and Redeemable warrants included as part of the Units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.
お知らせ • Oct 17The Staff of NYSE Regulation Files Form 25 with the SEC to Remove Enphys Acquisition's Class A Ordinary Shares, Units from Listing and Registration on the New York Stock ExchangeAs previously reported by Enphys Acquisition Corp. (the ‘Company’), on July 24, 2024, the staff of NYSE Regulation (the ‘Staff’), on behalf of the New York Stock Exchange (‘NYSE’), commenced proceedings to delist the Company’s Class A ordinary shares, par value $0.0001 per share (‘Class A Ordinary Shares’), units, each consisting of one Class A Ordinary Share and one-half of one redeemable warrant (the ‘Units’), with each warrant exercisable for one share of Class A Ordinary Share of the Company (the ‘Warrants’), and Warrants from the NYSE pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. Trading in the Class A Ordinary Shares, Units, and Warrants on the NYSE was suspended after the market closed on July 24, 2024. Effective as of and since July 25, 2024, the Class A Ordinary Shares, Units, and Warrants have been quoted and traded on the OTC Pink Marketplace under the ticker symbols ‘NFSCF,’ ‘NFSUF,’ and ‘NFSWF,’ respectively. The Company timely exercised its right to a review of the Staff’s determination by a committee (the ‘Committee’) of the Board of Directors of the NYSE. On October 10, 2024, the Company withdrew its request for review by the Committee. On October 10, 2024, the Staff filed a Form 25 with the Securities and Exchange Commission (the ‘SEC’) to remove the Company’s Class A Ordinary Shares, Units, and Warrants from listing and registration on the NYSE. The delisting will be effective 10 days following the date of filing of the Form 25. The Company’s Class A Ordinary Shares, Units, and Warrants will continue to trade on the OTC Pink Marketplace following the delisting.
お知らせ • Aug 14Enphys Acquisition Corp. announced delayed 10-Q filingOn 08/13/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 26NYSE to Commence Delisting Proceedings Against Enphys AcquisitionThe New York Stock Exchange LLC announced that the staff of NYSE Regulation has determined to commence proceedings to delist Class A ordinary shares, par value 0.0001 per share; Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant and Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary shares at an exercise price of 11.50 of Enphys Acquisition Corp. (the “Company”) from the NYSE. Trading in the Company’s Securities will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s Securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s Securities upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
お知らせ • May 17Enphys Acquisition Corp. announced delayed 10-Q filingOn 05/15/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 31Enphys Acquisition Corp. Units, Each Consisting of One Class A Ordinary Share and One-Half of One Redeemable Warrant Deleted from OTC EquityEnphys Acquisition Corp. Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant has been deleted from OTC Equity effective December 30, 2024, due to Unit Separation.
お知らせ • Nov 15Enphys Acquisition Corp. Files Form 15Enphys Acquisition Corp. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Units, each consisting of one Class A ordinary share, and one-half of one redeemable warrant; Class A ordinary shares included as part of the Units, par value $0.0001 per share and Redeemable warrants included as part of the Units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share under the Securities Exchange Act of 1934, as amended.
お知らせ • Oct 17The Staff of NYSE Regulation Files Form 25 with the SEC to Remove Enphys Acquisition's Class A Ordinary Shares, Units from Listing and Registration on the New York Stock ExchangeAs previously reported by Enphys Acquisition Corp. (the ‘Company’), on July 24, 2024, the staff of NYSE Regulation (the ‘Staff’), on behalf of the New York Stock Exchange (‘NYSE’), commenced proceedings to delist the Company’s Class A ordinary shares, par value $0.0001 per share (‘Class A Ordinary Shares’), units, each consisting of one Class A Ordinary Share and one-half of one redeemable warrant (the ‘Units’), with each warrant exercisable for one share of Class A Ordinary Share of the Company (the ‘Warrants’), and Warrants from the NYSE pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. Trading in the Class A Ordinary Shares, Units, and Warrants on the NYSE was suspended after the market closed on July 24, 2024. Effective as of and since July 25, 2024, the Class A Ordinary Shares, Units, and Warrants have been quoted and traded on the OTC Pink Marketplace under the ticker symbols ‘NFSCF,’ ‘NFSUF,’ and ‘NFSWF,’ respectively. The Company timely exercised its right to a review of the Staff’s determination by a committee (the ‘Committee’) of the Board of Directors of the NYSE. On October 10, 2024, the Company withdrew its request for review by the Committee. On October 10, 2024, the Staff filed a Form 25 with the Securities and Exchange Commission (the ‘SEC’) to remove the Company’s Class A Ordinary Shares, Units, and Warrants from listing and registration on the NYSE. The delisting will be effective 10 days following the date of filing of the Form 25. The Company’s Class A Ordinary Shares, Units, and Warrants will continue to trade on the OTC Pink Marketplace following the delisting.
お知らせ • Aug 14Enphys Acquisition Corp. announced delayed 10-Q filingOn 08/13/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 26NYSE to Commence Delisting Proceedings Against Enphys AcquisitionThe New York Stock Exchange LLC announced that the staff of NYSE Regulation has determined to commence proceedings to delist Class A ordinary shares, par value 0.0001 per share; Units, each consisting of one Class A ordinary share and one-half of one redeemable warrant and Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary shares at an exercise price of 11.50 of Enphys Acquisition Corp. (the “Company”) from the NYSE. Trading in the Company’s Securities will be suspended immediately. NYSE Regulation reached its decision to delist the Company’s Securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day period of at least $40,000,000. The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange. The NYSE will apply to the Securities and Exchange Commission to delist the Company’s Securities upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.
お知らせ • May 17Enphys Acquisition Corp. announced delayed 10-Q filingOn 05/15/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Enphys Acquisition Corp. announced delayed annual 10-K filingOn 04/01/2024, Enphys Acquisition Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Feb 15High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. CEO & Director Jorge De Cajal is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Nov 17Enphys Acquisition Corp. announced delayed 10-Q filingOn 11/15/2023, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 31Enphys Acquisition Corp. announced that it has received $0.3 million in fundingEnphys Acquisition Corp. announced a private placement of non-convertible promissory note to Enphys Acquisition Sponsor LLC in the principal amount of $300,000 on October 30, 2023. The issuance of the Promissory Note was made pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended. Under the terms of the promissory note, the company may request from time to time prior to the maturity date, up to $300,000 in drawdowns on the principal. Each drawdown request must state the amount to be drawn down, and must not be an amount less than $10,000 unless agreed upon by the company and the payee. Payee shall fund each drawdown request no later than (3) business days after receipt of a drawdown request; provided, however, that the maximum amount of drawdowns outstanding under the promissory note at any time may not exceed $300,000. No fees, payments or other amounts shall be due to the payee in connection with, or as a result of, any drawdown request by the company.
お知らせ • Oct 11Enphys Acquisition Corp. announced that it expects to receive $0.4 million in fundingEnphys Acquisition Corp. announced a private placement of non-convertible promissory note to Enphys Acquisition Sponsor LLC in the principal amount of $400,000 on October 10, 2023. Payee or one or more of its affiliates or designees will deposit into the company’s trust account established in connection with its initial public offering an amount equal to the lesser of $0.025 per Class A ordinary share of the company multiplied by the number of Class A ordinary shares of the Company then outstanding and $100,000, for each calendar month until the earlier of the company’s completion of a business combination and February 8, 2024. No interest shall be payable on this note.
お知らせ • May 16Enphys Acquisition Corp. announced delayed 10-Q filingOn 05/15/2023, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 16Enphys Acquisition Corp. announced delayed 10-Q filingOn 11/15/2022, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Enphys Acquisition Corp. announced delayed 10-Q filingOn 05/16/2022, Enphys Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 23Enphys Acquisition Announces Receipt of Notice of Late Filing from New York Stock ExchangeOn April 18, 2022, Enphys Acquisition Corp. ("the Company") received a notice from the New York Stock Exchange ("the NYSE") indicating that the Company is not in compliance with Section 802.01E of the NYSE Listed CompanyManual as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2021 ("the Form 10-K") with the Securities and Exchange Commission ("the SEC"). The NYSE informed the Company that, under NYSE rules, the Company will have six months from April 18, 2022 to file the Form 10-K with the SEC. The Company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-K. If the Company fails to file the Form 10-K before the NYSE's compliance deadline, the NYSE may grant, at its sole discretion, an extension of up to six additional months for the Company to regain compliance, depending on the specific circumstances. The notice from the NYSE also notes that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant. Reference is made to the Notification of Late Filing on Form 12b-25 filed by the Company with the Commission on April 1, 2022 (the Form 12b-25") reporting that it required additional time to complete the Form 10-K. Although the Company has dedicated significant resources to the completion of finalizing its audited consolidated financial statements and related disclosures for inclusion in the Form 10-K, the Company is unable to file the Form 10-K prior to April 15, 2022, the extension period provided by the Form 12b-25. Additional time is needed by the Company to complete its review of the financial statements included in the Form 10-K in order to ensure a complete, accurate Annual Report. The delay is due primarily to additional information needed in relation to the Company's financial statements to complete the audit. The Company is working diligently to ensure accurate disclosures are made in the Form 10-K and expects to file the Form 10-K on or about April 27, 2022, or soon thereafter.
お知らせ • Apr 03Enphys Acquisition Corp. announced delayed annual 10-K filingOn 04/01/2022, Enphys Acquisition Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
